Author(s): Matthyssens LE, Creytens D, Ceelen WP
Abstract Share this page
Abstract Retroperitoneal liposarcoma (RLS) is a rare, biologically heterogeneous tumor that present considerable challenges due to its size and deep location. As a consequence, the majority of patients with high-grade RLS will develop locally recurrent disease following surgery, and this constitutes the cause of death in most patients. Here, we review current insights and controversies regarding histology, molecular biology, extent of surgery, (neo)adjuvant treatment, and systemic treatment including novel targeted agents in RLS.
This article was published in Front Surg
and referenced in Journal of Gastrointestinal & Digestive System